Allarity Therapeutics (NASDAQ:ALLR) Given New $9.75 Price Target at Ascendiant Capital Markets

Allarity Therapeutics (NASDAQ:ALLR) had its target price lifted by research analysts at Ascendiant Capital Markets from $9.50 to $9.75 in a research note issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Allarity Therapeutics in a report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $9.75.

Allarity Therapeutics Stock Performance

Allarity Therapeutics stock opened at $1.15 on Friday. Allarity Therapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $2.35. The company has a market capitalization of $18.19 million, a price-to-earnings ratio of -1.44 and a beta of 0.01. The stock has a fifty day moving average of $1.05 and a two-hundred day moving average of $1.19.

Allarity Therapeutics (NASDAQ:ALLR) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.01. On average, analysts forecast that Allarity Therapeutics will post -78.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Allarity Therapeutics

Hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC grew its position in shares of Allarity Therapeutics by 49.3% in the second quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock valued at $51,000 after purchasing an additional 16,729 shares during the period. Jane Street Group LLC acquired a new stake in Allarity Therapeutics in the 2nd quarter worth about $27,000. XTX Topco Ltd acquired a new stake in Allarity Therapeutics in the 4th quarter worth about $36,000. Citadel Advisors LLC purchased a new stake in Allarity Therapeutics in the 3rd quarter valued at about $149,000. Finally, Capital Advisors Inc. OK acquired a new position in shares of Allarity Therapeutics during the 4th quarter valued at about $108,000. Institutional investors and hedge funds own 11.53% of the company’s stock.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.